SCHEMBL1481501

SCHEMBL1481501

COc1ccc(/C=C/c2nc(-c3ccc(Cl)cc3Cl)c[nH]2)c(OC)c1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AMY1A P0DUB6 3/20 0.45
CYP1A1 P04798 2/20 0.41
CYP1B1 Q16678 2/20 0.41
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
PDGFRB P09619 3/20 0.39
CYP19A1 P11511 1/20 0.38
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TP53 P04637 1/20 0.36
ALDH1A1 P00352 1/20 0.36
ALPL P05186 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
ALPG P10696 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481504 1.00 AMY1A (0.45) AMY1ACYP1A1CYP1B1KDM4EMAPT
SCHEMBL1480665 0.84 HPGD (0.48) AMY1ACYP1A1CYP1B1KDM4EMAPT
SCHEMBL1480661 0.84 HPGD (0.48) AMY1ACYP1A1CYP1B1KDM4EMAPT
SCHEMBL1481897 0.84 AMY1A (0.43) AMY1AKDM4EMAPTNPC1RAB9A
SCHEMBL1481896 0.84 AMY1A (0.43) AMY1AKDM4EMAPTNPC1RAB9A
SCHEMBL1480968 0.82 ACHE (0.45) CYP1A1CYP1B1KDM4EMAPTCYP19A1
SCHEMBL1480971 0.82 ACHE (0.45) CYP1A1CYP1B1KDM4EMAPTCYP19A1
SCHEMBL12828682 0.81 DPP4 (0.38) CYP1A1CYP1B1KDM4EMAPTPDGFRB
SCHEMBL1480762 0.80 MEN1 (0.37) AMY1ACYP1A1CYP1B1KDM4EMAPT
SCHEMBL1480765 0.80 MEN1 (0.37) AMY1ACYP1A1CYP1B1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ AMY1A 1384/4885CYP1A1 697/4885CYP1B1 345/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ AMY1A 1384/4885CYP1A1 697/4885CYP1B1 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.